Who are Nadroparin Calcium and Warfarin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nadroparin-calcium-and-warfarin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nadroparin Calcium and Warfarin — Competitive Intelligence Brief

Nadroparin Calcium and Warfarin (Nadroparin Calcium and Warfarin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist). Area: Cardiovascular.

marketed Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist) Antithrombin III (nadroparin); Vitamin K-dependent clotting factors II, VII, IX, X (warfarin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Nadroparin Calcium and Warfarin (Nadroparin Calcium and Warfarin) — Shanghai Zhongshan Hospital. Nadroparin calcium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing antithrombin III activity, while warfarin is a vitamin K antagonist that inhibits synthesis of vitamin K-dependent clotting factors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nadroparin Calcium and Warfarin TARGET	Nadroparin Calcium and Warfarin	Shanghai Zhongshan Hospital	marketed	Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist)	Antithrombin III (nadroparin); Vitamin K-dependent clotting factors II, VII, IX, X (warfarin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist) class)

Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nadroparin Calcium and Warfarin — Competitive Intelligence Brief. https://druglandscape.com/ci/nadroparin-calcium-and-warfarin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab